Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Authors:
Michael B. Streiff The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Search for other papers by Michael B. Streiff in
Current site
Google Scholar
PubMed
Close
 MD
,
Bjorn Holmstrom Moffitt Cancer Center

Search for other papers by Bjorn Holmstrom in
Current site
Google Scholar
PubMed
Close
 MD
,
Dana Angelini Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Search for other papers by Dana Angelini in
Current site
Google Scholar
PubMed
Close
 MD
,
Aneel Ashrani Mayo Clinic Comprehensive Cancer Center

Search for other papers by Aneel Ashrani in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Tyler Buckner University of Colorado Cancer Center

Search for other papers by Tyler Buckner in
Current site
Google Scholar
PubMed
Close
 MD, MSc
,
Robert Diep Stanford Cancer Institute

Search for other papers by Robert Diep in
Current site
Google Scholar
PubMed
Close
,
Kleber Yotsumoto Fertrin Fred Hutchinson Cancer Center

Search for other papers by Kleber Yotsumoto Fertrin in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Annemarie E. Fogerty Mass General Cancer Center

Search for other papers by Annemarie E. Fogerty in
Current site
Google Scholar
PubMed
Close
 MD
,
Nicolas Gallastegui Crestani The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Search for other papers by Nicolas Gallastegui Crestani in
Current site
Google Scholar
PubMed
Close
 MD
,
Radhika Gangaraju O’Neal Comprehensive Cancer Center at UAB

Search for other papers by Radhika Gangaraju in
Current site
Google Scholar
PubMed
Close
 MD, MSPH
,
Cristhiam Rojas-Hernandez The University of Texas MD Anderson Cancer Center

Search for other papers by Cristhiam Rojas-Hernandez in
Current site
Google Scholar
PubMed
Close
 MD
,
Samuel Z. Goldhaber Dana-Farber/Brigham and Women’s Cancer Center

Search for other papers by Samuel Z. Goldhaber in
Current site
Google Scholar
PubMed
Close
 MD
,
Ibrahim Ibrahim UT Southwestern Simmons Comprehensive Cancer Center

Search for other papers by Ibrahim Ibrahim in
Current site
Google Scholar
PubMed
Close
 MD
,
Timothy Kubal Moffitt Cancer Center

Search for other papers by Timothy Kubal in
Current site
Google Scholar
PubMed
Close
 MD, MBA
,
Andrew D. Leavitt UCSF Helen Diller Family Comprehensive Cancer Center

Search for other papers by Andrew D. Leavitt in
Current site
Google Scholar
PubMed
Close
 MD
,
Ming Lim Huntsman Cancer Institute at the University of Utah

Search for other papers by Ming Lim in
Current site
Google Scholar
PubMed
Close
 MD
,
Janelle Mann Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Search for other papers by Janelle Mann in
Current site
Google Scholar
PubMed
Close
 PharmD, BCOP
,
Simon Mantha Memorial Sloan Kettering Cancer Center

Search for other papers by Simon Mantha in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Colleen Morton Vanderbilt-Ingram Cancer Center

Search for other papers by Colleen Morton in
Current site
Google Scholar
PubMed
Close
 MD, MBBCh
,
Alex Nester Fred & Pamela Buffett Cancer Center

Search for other papers by Alex Nester in
Current site
Google Scholar
PubMed
Close
 MD
,
Andrew O’Brien Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Search for other papers by Andrew O’Brien in
Current site
Google Scholar
PubMed
Close
 MD
,
Thomas L. Ortel Duke Cancer Institute

Search for other papers by Thomas L. Ortel in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Alexander Pine Yale Cancer Center/Smilow Cancer Hospital

Search for other papers by Alexander Pine in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Allyson Pishko Abramson Cancer Center at the University of Pennsylvania

Search for other papers by Allyson Pishko in
Current site
Google Scholar
PubMed
Close
 MD
,
Mona Ranade UCLA Jonsson Comprehensive Cancer Center

Search for other papers by Mona Ranade in
Current site
Google Scholar
PubMed
Close
 MD
,
Amirali Salmasi UC San Diego Moores Cancer Center

Search for other papers by Amirali Salmasi in
Current site
Google Scholar
PubMed
Close
 MD
,
Jordan Schaefer University of Michigan Rogel Cancer Center

Search for other papers by Jordan Schaefer in
Current site
Google Scholar
PubMed
Close
 MD
,
Eliot Williams University of Wisconsin Carbone Cancer Center

Search for other papers by Eliot Williams in
Current site
Google Scholar
PubMed
Close
 MD
,
Geoffrey Wool The UChicago Medicine Comprehensive Cancer Network

Search for other papers by Geoffrey Wool in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Theodore Wun UC Davis Comprehensive Cancer Center

Search for other papers by Theodore Wun in
Current site
Google Scholar
PubMed
Close
 MD
,
Sarah Montgomery National Comprehensive Cancer Network

Search for other papers by Sarah Montgomery in
Current site
Google Scholar
PubMed
Close
 BA
,
Jamie Nguyen National Comprehensive Cancer Network

Search for other papers by Jamie Nguyen in
Current site
Google Scholar
PubMed
Close
 PharmD
,
Deborah Freedman-Cass National Comprehensive Cancer Network

Search for other papers by Deborah Freedman-Cass in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Bailee Sliker National Comprehensive Cancer Network

Search for other papers by Bailee Sliker in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.

Discussion Writing Committee Members

Michael B. Streiff, Robert Diep, Radhika Gangaraju, Cristhiam Rojas-Hernandez, Ming Lim, and Colleen Morton

To view disclosures of external relationships for the NCCN Guidelines panel, go to https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panels

The full NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease are not printed in this issue of JNCCN. The complete and most recent version of these guidelines is available free of charge at NCCN.org.

NCCN CATEGORIES OF EVIDENCE AND CONSENSUS

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN CATEGORIES OF PREFERENCE

Preferred intervention: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.

Other recommended intervention: Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.

Useful in certain circumstances: Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.

Clinical trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PLEASE NOTE

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

  • Collapse
  • Expand
  • 1.

    Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715722.

  • 2.

    Mulder FI, Horvath-Puho E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137:19591969.

  • 3.

    Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 2013;119:648655.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632634.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:23392346.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484490.

  • 7.

    Fotopoulou C, duBois A, Karavas AN, et al. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 2008;26:26832689.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458464.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Chew HK, Wun T, Harvey DJ, et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:7076.

  • 10.

    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:18461850.

  • 11.

    Kuderer NM, Francis CW, Culakova E, et al. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy (abstract). J Clin Oncol 2008;26:95219521.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Martino MA, Williamson E, Siegfried S, et al. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol 2005;98:289293.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:8995.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Ohashi Y, Ikeda M, Kunitoh H, et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol 2020;50:12461253.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001;106:612.

  • 16.

    Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38:496520.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016;17:e452e466.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445453.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Aggarwal A, Fullam L, Brownstein AP, et al. Deep vein thrombosis (DVT) and pulmonary embolism (PE): awareness and prophylaxis practices reported by patients with cancer. Cancer Invest 2015;33:405410.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Secin FP, Jiborn T, Bjartell AS, et al. Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008;53:134145.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Girard P, Decousus M, Laporte S, et al. PREPIC Study Group Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med 2001;164:10331037.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933938.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA 2014;311:717728.

  • 24.

    PubMed Overview. Accessed June 5, 2024. Available at: https://pubmed.ncbi.nlm.nih.gov/about/

    • PubMed
    • Export Citation
  • 25.

    Decousus H, Quere I, Presles E, et al. POST (Prospective Observational Superficial Thrombophlebitis) Study Group Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 2010;152:218224.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Gorty S, Patton-Adkins J, DaLanno M, et al. Superficial venous thrombosis of the lower extremities: analysis of risk factors, and recurrence and role of anticoagulation. Vasc Med 2004;9:16.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Periard D, Monney P, Waeber G, et al. Randomized controlled trial of peripherally inserted central catheters vs. peripheral catheters for middle duration in-hospital intravenous therapy. J Thromb Haemost 2008;6:12811288.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Galanaud JP, Blaise S, Sevestre MA, et al. OPTIMEV-SFMV investigators Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res 2018;171:179186.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Hirmerová J, Seidlerová J, Šubrt I, Hajšmanová Z. Prevalence of cancer in patients with superficial vein thrombosis and its clinical importance. J Vasc Surg Venous Lymphat Disord 2021;10:2632.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    van Weert H, Dolan G, Wichers I, et al. Spontaneous superficial venous thrombophlebitis: does it increase risk for thromboembolism? A historic follow-up study in primary care. J Fam Pract 2006;55:5257.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Lutter KS, Kerr TM, Roedersheimer LR, et al. Superficial thrombophlebitis diagnosed by duplex scanning. Surgery 1991;110:4246.

  • 32.

    Sullivan V, Denk PM, Sonnad SS, et al. Ligation versus anticoagulation: treatment of above-knee superficial thrombophlebitis not involving the deep venous system. J Am Coll Surg 2001;193:556562.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Chengelis DL, Bendick PJ, Glover JL, et al. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg 1996;24:745749.

  • 34.

    Barco S, Pomero F, Di Minno MND, et al. Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study. J Thromb Haemost 2017;15:21762183.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Galanaud JP, Bosson JL, Genty C, et al. Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies. J Thromb Haemost 2012;10:10041011.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Beyer-Westendorf J, Schellong SM, Gerlach H, et al. SURPRISE investigators Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017;4:e105e113.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Kearon C, Carrier M, Gu CS, et al. Rivaroxaban compared to placebo for the treatment of leg superficial vein thrombosis: a randomized trial. Semin Thromb Hemost 2020;46:977985.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Decousus H, Prandoni P, Mismetti P, et al. CALISTO Study Group Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010;363:12221232.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:17.

  • 40.

    Galanaud JP, Sevestre MA, Pernod G, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost 2017;15:907916.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Poudel SK, Park DY, Jia X, et al. Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: the Cleveland Clinic experience. J Thromb Haemost 2020;18:651659.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Dentali F, Pegoraro S, Barco S, et al. Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. J Thromb Haemost 2017;15:17571763.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Decousus H, Bourmaud A, Fournel P, et al. ONCOCIP Investigators Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood 2018;132:707716.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Bleker SM, van Es N, van Gils L, et al. Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review. Thromb Res 2016;140 Suppl 1:S8188.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Munoz FJ, Mismetti P, Poggio R, et al. RIETE Investigators Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008;133:143148.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Agnelli G, Verso M, Ageno W, et al. MASTER investigators The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008;121:605610.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Beck-Razi N, Kuzmin A, Koren D, et al. Asymptomatic deep vein thrombosis in advanced cancer patients: the value of venous sonography. J Clin Ultrasound 2010;38:232237.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Birdwell BG, Raskob GE, Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 1998;128:17.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Taffoni MJ, Ravenel JG, Ackerman SJ. Prospective comparison of indirect CT venography versus venous sonography in ICU patients. AJR Am J Roentgenol 2005;185:457462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Lim K-E, Hsu W-C, Hsu Y-Y, et al. Deep venous thrombosis: comparison of indirect multidetector CT venography and sonography of lower extremities in 26 patients. Clin Imaging 2004;28:439444.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol 2007;17:175181.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Evans AJ, Sostman HD, Witty LA, et al. Detection of deep venous thrombosis: prospective comparison of MR imaging and sonography. J Magn Reson Imaging 1996;6:4451.

  • 53.

    Laissy JP, Cinqualbre A, Loshkajian A, et al. Assessment of deep venous thrombosis in the lower limbs and pelvis: MR venography versus duplex Doppler sonography. AJR Am J Roentgenol 1996;167:971975.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Dupas B, el Kouri D, Curtet C, et al. Angiomagnetic resonance imaging of iliofemorocaval venous thrombosis. Lancet 1995;346:1719.

  • 55.

    Fraser DGW, Moody AR, Davidson IR, et al. Deep venous thrombosis: diagnosis by using venous enhanced subtracted peak arterial MR venography versus conventional venography. Radiology 2003;226:812820.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Carpenter JP, Holland GA, Baum RA, et al. Magnetic resonance venography for the detection of deep venous thrombosis: comparison with contrast venography and duplex Doppler ultrasonography. J Vasc Surg 1993;18:734741.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Baarslag HJ, Koopman MMW, Hutten BA, et al. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004;15:503507.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Joffe HV, Kucher N, Tapson VF, Goldhaber SZ, Deep Vein Thrombosis (DVT) FREE Steering Committee Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004;110:16051611.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:5762.

  • 60.

    Lee AYY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:14041408.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Verso M, Agnelli G, Kamphuisen PW, et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 2008;3:117122.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Baarslag H-J, van Beek EJR, Koopman MMW, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002;136:865872.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Kahn SR, Shapiro S, Wells PS, et al. SOX trial investigators Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014;383:880888.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800809.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004:CD001100

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Napolitano M, Saccullo G, Malato A, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol 2014;32:36073612.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Moik F, Colling M, Mahe I, et al. Extended anticoagulation treatment for cancer-associated thrombosis-rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost 2022;20:619634.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 2019;17:18661874.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007;5:16501653.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Davies GA, Lazo-Langner A, Gandara E, et al. A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2). Thromb Res 2018;162:8892.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:13861389.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Kanne JP, Lalani TA. Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. Circulation 2004;109:I1521.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Schoepf UJ, Costello P. CT angiography for diagnosis of pulmonary embolism: state of the art. Radiology 2004;230:329337.

  • 74.

    Schoepf UJ, Kucher N, Kipfmueller F, et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004;110:32763280.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Plasencia-Martinez JM, Carmona-Bayonas A, Calvo-Temprano D, et al. Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: data from a multicenter cohort study. Eur J Radiol 2017;87:6675.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Anderson DR, Kahn SR, Rodger MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA 2007;298:27432753.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Calvo-Romero JM, Lima-Rodríguez EM, Bureo-Dacal P, Pérez-Miranda M. Predictors of an intermediate ventilation/perfusion lung scan in patients with suspected acute pulmonary embolism. Eur J Emerg Med 2005;12:129131.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Kearon C, Ginsberg JS, Douketis J, et al. Canadian Pulmonary Embolism Diagnosis Study (CANPEDS) Group An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med 2006;144:812821.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349:12271235.

  • 80.

    Sohne M, Kruip MJHA, Nijkeuter M, et al. Christoper Study Group Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost 2006;4:10421046.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Knowlson L, Bacchu S, Paneesha S, et al. Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol 2010;63:818822.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Maestre A, Trujillo-Santos J, Visona A, et al. RIETE Investigators D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer. Thromb Res 2014;133:384389.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Douma RA, van Sluis GL, Kamphuisen PW, et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 2010;104:831836.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Righini M, Le Gal G, De Lucia S, et al. Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost 2006;95:715719.

  • 85.

    Di Nisio M, Sohne M, Kamphuisen PW, Büller HR. D-Dimer test in cancer patients with suspected acute pulmonary embolism. J Thromb Haemost 2005;3:12391242.

  • 86.

    Jimenez D, Aujesky D, Moores L, et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011;66:7581.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Jimenez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest 2007;132:2430.

  • 88.

    Sanchez O, Trinquart L, Caille V, et al. Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. Am J Respir Crit Care Med 2010;181:168173.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:11651171.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Jimenez D, Diaz G, Molina J, et al. Troponin I and risk stratification of patients with acute nonmassive pulmonary embolism. Eur Respir J 2008;31:847853.

  • 91.

    Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007;116:427433.

  • 92.

    Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:12631268.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Jimenez D, Aujesky D, Diaz G, et al. RIETE Investigators Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010;181:983991.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Pruszczyk P, Torbicki A, Kuch-Wocial A, et al. Diagnostic value of transoesophageal echocardiography in suspected haemodynamically significant pulmonary embolism. Heart 2001;85:628634.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997;134:479487.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Aujesky D, Roy PM, Le Manach CP, et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 2006;27:476481.

  • 97.

    Donze J, Le Gal G, Fine MJ, et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008;100:943948.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Weeda ER, Kohn CG, Peacock WF, et al. External validation of the hestia criteria for identifying acute pulmonary embolism patients at low risk of early mortality. Clin Appl Thromb Hemost 2017;23:769774.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006;144:165171.

  • 100.

    Ahn S, Lee YS, Kim WY, et al. Prognostic value of treatment setting in patients with cancer having pulmonary embolism: comparison with the pulmonary embolism severity index. Clin Appl Thromb Hemost 2017;23:615621.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    den Exter PL, Gomez V, Jimenez D, et al. Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. Chest 2013;143:138145.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Kline JA, Roy PM, Than MP, et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE-C tool. Thromb Res 2012;129:e194-199e199.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Carmona-Bayonas A, Jimenez-Fonseca P, Font C, et al. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Br J Cancer 2017;116:9941001.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Font C, Carmona-Bayonas A, Beato C, et al. Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J 2017;49:1600282.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Ahn S, Cooksley T, Banala S, et al. Validation of the EPIPHANY index for predicting risk of serious complications in cancer patients with incidental pulmonary embolism. Support Care Cancer 2018;26:36013607.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Li X, Hu Y, Lin P, et al. Comparison of different clinical prognostic scores in patients with pulmonary embolism and active cancer. Thromb Haemost 2021;121:834844.

  • 107.

    Font C, Carmona-Bayonas A, Fernandez-Martinez A, et al. Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients. J Natl Compr Canc Netw 2014;12:365373.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Carmona-Bayonas A, Font C, Jimenez-Fonseca P, et al. Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism. Thromb Res 2016;143:7685.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419Se496S.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Jaff MR, McMurtry MS, Archer SL, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123:17881830.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Weingart S. AHA PE Guidelines. EMCrit Blog 2011.

  • 112.

    Pasrija C, Kronfli A, George P, et al. Utilization of veno-arterial extracorporeal membrane oxygenation for massive pulmonary embolism. Ann Thorac Surg 2018;105:498504.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Streiff MB. Thrombosis in the setting of cancer. Hematology Am Soc Hematol Educ Program 2016;2016:196205.

  • 114.

    Konstantinides S, Geibel A, Heusel G, et al. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:11431150.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Ashton RW, Daniels CE, Ryu JH. Thrombolytic therapy in patients with submassive pulmonary embolism. N Engl J Med 2003;348:357359.; author reply 357-359.

  • 116.

    Thabut G, Logeart D. Thrombolysis for pulmonary embolism in patients with right ventricular dysfunction: con. Arch Intern Med 2005;165:22002203.

  • 117.

    Meyer G, Vicaut E, Danays T, et al. PEITHO Investigators Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014;370:14021411.

  • 118.

    Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014;311:24142421.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Dong BR, Hao Q, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2009:CD004437

  • 120.

    Tardy B, Venet C, Zeni F, et al. Short term effect of recombinant tissue plasminogen activator in patients with hemodynamically stable acute pulmonary embolism: results of a meta-analysis involving 464 patients. Thromb Res 2009;124:672677.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002;162:25372541.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002;40:16601667.

  • 123.

    Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004;110:744749.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Kim HS, Preece SR, Black JH, et al. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg 2008;47:388394.

  • 125.

    Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002;105:14161419.

  • 126.

    Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005;129:10181023.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Thistlethwaite PA, Kemp A, Du L, et al. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2006;131:307313.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Kucher N, Boekstegers P, Muller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014;129:479486.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004;164:15411545.

  • 130.

    Streiff MB. Vena caval filters: a comprehensive review. Blood 2000;95:36693677.

  • 131.

    Streiff MB. Vena caval filters: a review for intensive care specialists. J Intensive Care Med 2003;18:5979.

  • 132.

    PREPIC Study Group Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005;112:416422.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409415.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:16531661.

  • 135.

    Mismetti P, Laporte S, Pellerin O, et al. PREPIC2 Study Group Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA 2015;313:16271635.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Ho KM, Rao S, Honeybul S, et al. A multicenter trial of vena cava filters in severely injured patients. N Engl J Med 2019;381:328337.

  • 137.

    Connolly GC, Chen R, Hyrien O, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008;122:299306.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:18621868.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Rabe C, Pilz T, Klostermann C, et al. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001;7:208215.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:12741283.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007;102:24642470.

  • 142.

    Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010;8:200205.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Janssen HL, Wijnhoud A, Haagsma EB, et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001;49:720724.

  • 144.

    Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg 2008;95:12451251.

  • 145.

    Hedayati N, Riha GM, Kougias P, et al. Prognostic factors and treatment outcome in mesenteric vein thrombosis. Vasc Endovascular Surg 2008;42:217224.

  • 146.

    Acosta S, Ogren M, Sternby NH, et al. Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. J Vasc Surg 2005;41:5963.

  • 147.

    Krauth MT, Lechner K, Neugebauer EA, Pabinger I. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention–an unresolved issue. Haematologica 2008;93:12271232.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Stamou KM, Toutouzas KG, Kekis PB, et al. Prospective study of the incidence and risk factors of postsplenectomy thrombosis of the portal, mesenteric, and splenic veins. Arch Surg 2006;141:663669.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Ageno W, Dentali F, Squizzato A. How I treat splanchnic vein thrombosis. Blood 2014;124:36853691.

  • 150.

    Butler JR, Eckert GJ, Zyromski NJ, et al. Natural history of pancreatitis-induced splenic vein thrombosis: a systematic review and meta-analysis of its incidence and rate of gastrointestinal bleeding. HPB (Oxford) 2011;13:839845.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Valla D, Dhumeaux D, Babany G, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology 1987;93:569575.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490497.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Dahabreh IJ, Zoi K, Giannouli S, et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009;33:6773.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009;113:56175623.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    Valla D, Le MG, Poynard T, et al. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986;90:807811.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:10541061.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:11441148.

  • 158.

    Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:17791790.

  • 159.

    Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387397.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708714.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010;5:487494.

  • 162.

    Regina S, Herault O, D’Alteroche L, et al. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859861.

  • 163.

    Colaizzo D, Amitrano L, Tiscia GL, et al. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007;110:27682769.

  • 164.

    Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:12531258.

  • 165.

    Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996;348:573577.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    Hoekstra J, Leebeek FW, Plessier A, et al. European Network for Vascular Disorders of the Liver Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 2009;51:696706.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 167.

    Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001;345:16831688.

  • 168.

    Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004;350:578585.

  • 169.

    Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010;123:111119.

  • 170.

    Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. European Network for Vascular Disorders of the Liver (EN-Vie) Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010;51:210218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol 2007;7:34.

  • 172.

    Bradbury MS, Kavanagh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. Radiographics 2002;22:527541.

  • 173.

    Hoekstra J, Janssen HL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med 2008;66:334339.

  • 174.

    Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med 2009;67:4653.

  • 175.

    Ponziani FR, Zocco MA, Campanale C, et al. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol 2010;16:143155.

  • 176.

    Dentali F, Ageno W, Witt D, et al. WARPED consortium Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost 2009;102:501504.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Candeloro M, Valeriani E, Monreal M, et al. Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Adv 2022;6:45164523.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008;112:48184823.

  • 179.

    Hollingshead M, Burke CT, Mauro MA, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005;16:651661.

  • 180.

    Kim HS, Patra A, Khan J, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radiol 2005;16:16851691.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Sharma S, Texeira A, Texeira P, et al. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004;40:172180.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Smalberg JH, Spaander MV, Jie KS, et al. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost 2008;100:10841088.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Garcia-Pagan JC, Heydtmann M, Raffa S, et al. Budd-Chiari Syndrome-Transjugular Intrahepatic Portosystemic Shunt Group TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008;135:808815.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. EN-Vie (European Network for Vascular Disorders of the Liver) Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009;151:167175.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006;55:878884.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Mancuso A, Fung K, Mela M, et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 2003;38:751754.

  • 187.

    Perello A, Garcia-Pagan JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002;35:132139.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 188.

    Rossle M, Olschewski M, Siegerstetter V, et al. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery 2004;135:394403.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    Hemming AW, Langer B, Greig P, et al. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 1996;171:176180.; discussion 180-171.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 190.

    Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999;30:8489.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Panis Y, Belghiti J, Valla D, et al. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery 1994;115:276281.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 192.

    Pisani-Ceretti A, Intra M, Prestipino F, et al. Surgical and radiologic treatment of primary Budd-Chiari syndrome. World J Surg 1998;22:4853.; discussion 53-44.

  • 193.

    Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg 2001;233:522527.

  • 194.

    Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500508.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 195.

    Psilopoulos D, Galanis P, Goulas S, et al. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 2005;17:11111117.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 196.

    Perez-Ayuso RM, Valderrama S, Espinoza M, et al. Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices. Ann Hepatol 2010;9:1522.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 197.

    Lay CS, Tsai YT, Lee FY, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006;21:413419.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Schepke M, Kleber G, Nurnberg D, et al. German Study Group for the Primary Prophylaxis of Variceal Bleeding Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:6572.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Sarin SK, Wadhawan M, Agarwal SR, et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005;100:797804.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 200.

    Sarin SK, Gupta N, Jha SK, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010;139:12381245.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 201.

    Funakoshi N, Segalas-Largey F, Duny Y, et al. Benefit of combination beta-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 2010;16:59825992.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960;1:13091312.

  • 203.

    Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:17291735.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 204.

    Lee AYY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146153.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 205.

    Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:10621072.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 206.

    Akl EA, Kahale L, Neumann I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014;6:CD006649.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    Lee AY, Kamphuisen PW, Meyer G, et al. CATCH Investigators Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677686.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e24Se43S. S.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 209.

    Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e195Se226S. S.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022;162:e207e243.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 211.

    Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:340S380S.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 212.

    Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799808.

  • 213.

    Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699708.

  • 214.

    Prescribing information for apixaban tablets for oral use. 2021. Accessed June 3, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202155s034lbl.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 215.

    Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost